Determining a cancer prognosis
A technology for cancer and prognosis, applied in the direction of material inspection products, mass spectrometry, instruments, etc., can solve the problems of injury and inflammation, inappropriateness, and increased morbidity and mortality of NSCLC patients
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0143] Recent data suggest that tumor hypoxia is a powerful driver for the secretion of factors that promote metastatic dissemination 8,9 . A key component of secreted factors thought to be involved in enhancing metastasis is the release of exosomes. Accumulating evidence suggests that the rich array of proteomic and genomic information carried by tumor-derived exosomes is a novel mechanism by which cancer cells alter the behavior of surrounding stroma and malignant cells 10 . Exosomes Can Influence Participation in Neovascularization 11 , immunosuppressed 12 signaling process and induce drug resistance and oncogenic metastasis 13-15 . Furthermore, the ability of exosomes to induce systemic changes is thought to facilitate metastatic dissemination, which accounts for the vast majority of patient deaths 16 .
[0144] Exosomes have also been reported to transfer oncogenic proteins 14 . Exosome transfer in glioma cells has recently been shown to enhance tumorigenesis by ...
Embodiment 2
[0212] Despite significant therapeutic advances, lung cancer remains the leading cause of cancer-related death worldwide 1 . The overall five-year survival rate for patients with non-small cell lung cancer (NSCLC) is very poor, as low as 15% 2 . Biopsy is used to diagnose and type NSCLC, and TNM stage is the most important factor in predicting survival and guiding clinical intervention 2 . However, a large proportion of patients with early-stage and locally limited NSCLC have treatment-refractory disease or develop metastatic disease despite curative-intent treatment by surgical radiotherapy or chemoradiation, suggesting that TNM staging alone is insufficient to guide disease manage. Thus, there is a significant unmet clinical need to identify these patients who respond poorly to current treatments and allow tailored therapeutic interventions. Prognostic biomarkers, especially non-invasive fluid biomarkers, could allow clinicians to classify patients in need of intensive ...
PUM
| Property | Measurement | Unit |
|---|---|---|
| diameter | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


